Peptide Research
This page summarizes selected published studies on peptide-based research. The studies below tested specific compounds and study preparations under controlled protocols; their results do not establish the quality, safety, or effects of products sold elsewhere.
Retatrutide: Phase 2 obesity trial (2023)
Jastreboff and colleagues conducted a 48-week, randomized, double-blind, placebo-controlled Phase 2 trial in 338 adults with obesity or overweight plus a weight-related condition. In the 12 mg group, mean body-weight change at week 48 was −24.2%, compared with −2.1% with placebo. Gastrointestinal events were the most common adverse events; dose-related increases in heart rate were also reported. This was a Phase 2 study and does not settle long-term safety or outcomes.
Semaglutide: STEP 1 trial (2021)
Wilding and colleagues randomized 1,961 adults with overweight or obesity, without diabetes, to weekly semaglutide 2.4 mg or placebo for 68 weeks; both groups also received lifestyle intervention. Mean body-weight change was −14.9% with semaglutide and −2.4% with placebo. The result applies to the trial population, dose, preparation, and study conditions—not to peptides as a whole.
Source: Read the NEJM paper: Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021)
BPC-157: Achilles tendon study in rats (2003)
This laboratory study examined rats with transected Achilles tendons and tendon cells studied in vitro. The authors reported improved tendon-healing measures in the animal model and stimulated tendon-cell growth in vitro. These are preclinical findings; they do not demonstrate benefit or safety in people.
What reviews say about BPC-157 evidence
A 2025 systematic review identified 36 musculoskeletal studies published from 1993 to 2024: 35 were preclinical and one was clinical. The human report was a small retrospective series without a control group, so it cannot establish efficacy.
Source: Read the 2025 systematic review on PubMed
A separate human-evidence review published in 2026 found only three eligible studies, totaling 30 participants. The authors rated the studies as methodologically poor and the certainty of evidence as very low.
Source: Read the 2026 human-evidence systematic review on PubMed
How to interpret these studies
- Animal and cell findings are early-stage evidence and may not translate to humans.
- A result for one peptide, dose, formulation, or trial population cannot be assumed for another.
- Published study results do not verify the identity, purity, sterility, or performance of any retail product.
Research-use notice: This material is for educational purposes, not medical advice. Products presented for research are not intended for human or veterinary use, diagnosis, treatment, or prevention of disease. Follow applicable laws, institutional protocols, and product-specific safety documentation.
Selected studies last reviewed: October 2026.